Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) Bundle
From its founding on January 27, 1995 in Guiyang to a public listing on the Shenzhen Stock Exchange in April 2010, Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) has grown into a vertically integrated healthcare group employing 5,059 people as of December 31, 2024, with a diversified portfolio spanning traditional Chinese medicine, Chinese patent medicines and biologics, production bases for solid and injection preparations, and distribution and medical service channels; the company-ranked 42nd among the 2023 Guizhou Top 100 Enterprises and 5th among 2023 Guizhou Top 100 Private Enterprises-now carries a market capitalization of about 7.36 billion CNY (late 2025), reports operating cash flow that covers 132.6% of its debt, faces margin pressures with net profit margin at 1.3% (down from 3.5%), and relies on a management and board structure (average board tenure 2.1 years) and strategic partnerships to execute its mission of modernizing and internationalizing traditional Chinese medicine while generating revenue across manufacturing, distribution and services.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): Intro
History- Founded: January 27, 1995 in Guiyang, China.
- Listed: April 2010 on the Shenzhen Stock Exchange (ticker: 002390).
- Workforce: 5,059 employees as of December 31, 2024.
- Industrial integration: Developed a comprehensive healthcare industry chain covering medical services, pharmaceutical distribution, and manufacturing.
- Product scope: Traditional Chinese medicine (TCM), Chinese patent medicine, biological medicine, and related products.
- Awards & rankings: 42nd in the '2023 Guizhou Top 100 Enterprises' and 5th in the '2023 Guizhou Top 100 Private Enterprises.'
| Date | Event |
|---|---|
| 1995-01-27 | Company established in Guiyang, Guizhou Province. |
| 2010-04 | Listed on Shenzhen Stock Exchange (002390.SZ). |
| 2023 | Ranked 42nd among Guizhou Top 100 Enterprises; 5th among Guizhou Top 100 Private Enterprises. |
| 2024-12-31 | Reported 5,059 employees. |
- Publicly traded entity: Shares listed on Shenzhen Stock Exchange with institutional and retail shareholders.
- Group structure: Operates as an integrated group with subsidiaries and business units spanning manufacturing, distribution, and medical service platforms.
- Governance: Standard board and supervisory structure for a listed Chinese pharmaceutical company, emphasizing regulatory compliance and operational controls.
- Mission: To provide integrated healthcare solutions by combining traditional Chinese medicine heritage with modern biological medicines and downstream medical services.
- Strategic pillars: Vertical integration across R&D, manufacturing, distribution, and medical service delivery; expansion of TCM and biological portfolios; strengthening regional market leadership in Guizhou and neighboring provinces.
- R&D and product development: Internal and partnered development of TCM formulations, Chinese patent medicines, and biological products.
- Manufacturing: In-house GMP-compliant production facilities for pharmaceuticals and biologics to ensure supply consistency and cost control.
- Distribution: Wholesale and retail distribution channels, including pharmaceutical distributors, hospital procurement, and pharmacy networks.
- Medical services: Delivery of clinical services and disease-management programs that create demand for proprietary and distributed products.
- Regulatory & quality: Compliance with national drug regulations, quality control, and post-market surveillance to maintain market access and trust.
- Product sales: Revenues from sales of TCM products, Chinese patent medicines, and biological medicines to hospitals, pharmacies, and distributors.
- Distribution margins: Profit from wholesale distribution services and third-party product distribution across its logistics and sales network.
- Medical services & value-added services: Fees and service revenues from healthcare delivery, disease management programs, and integrated care initiatives.
- Contract manufacturing and partnerships: Income from toll manufacturing or co-development contracts with other pharmaceutical companies or research institutions.
| Metric | Value / Note |
|---|---|
| Employees (2024-12-31) | 5,059 |
| Listing | Shenzhen Stock Exchange, ticker 002390 (since April 2010) |
| Core product categories | Traditional Chinese Medicine, Chinese patent medicine, Biological medicine |
| 2023 Regional rankings | #42 Guizhou Top 100; #5 Guizhou Top 100 Private |
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): History
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) was founded as a regional pharmaceutical manufacturer in Guizhou province and listed on the Shenzhen Stock Exchange to access growth capital and broaden its investor base. Over the past decade the company expanded from traditional formulation manufacturing into enhanced R&D, strategic partnerships and acquisitions to scale production and enter higher-value therapeutic segments.- Listed entity: publicly traded on Shenzhen Stock Exchange (002390.SZ), free-float shares available to retail and institutional investors.
- Major shareholder: Guizhou Yibai Pharmaceutical Co., Ltd. - strategic controlling stake that guides long-term strategy and capital deployment.
- Management: Lingzhong Kong - General Manager and Director; executive team combines manufacturing, regulatory and commercial expertise.
- Board composition: directors with diverse backgrounds (industry, finance, regulatory affairs) supporting strategic decision-making and oversight.
- Strategic partnerships: technology and distribution alliances to strengthen market position, outsource capacity and accelerate new product launches.
| Item | Figure (latest reported) |
|---|---|
| Major shareholder (Guizhou Yibai Pharmaceutical Co., Ltd.) - stake | ~30-35% |
| Revenue (most recent fiscal year) | ≈ CNY 1.2 billion |
| Net profit (most recent fiscal year) | ≈ CNY 120 million |
| Total assets | ≈ CNY 2.3 billion |
| Market capitalization (approx.) | ≈ CNY 3.5-4.5 billion |
| Employees | ~1,200 |
- Manufacturing: produces finished-dose medicines (oral solids, injectables) under internal brands and OEM/contract manufacturing agreements.
- R&D and product lifecycle: invests in formulation improvement and registration to extend product exclusivity and margins.
- Sales & distribution: revenues from direct sales to hospitals, pharmacies and through distribution partners; margins boosted by proprietary products and higher-value formulations.
- Strategic investments: uses equity partnerships, minority stakes and capacity deals to secure raw-material supply, broaden distribution and obtain technology transfer.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): Ownership Structure
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) centers its corporate purpose on modernizing and internationalizing traditional Chinese medicine while integrating medical services, pharmaceutical distribution, and manufacturing to improve healthcare delivery.- Mission and Values: Committed to modernization and internationalization of traditional Chinese medicine; focused on high-quality pharmaceutical products to meet diverse medical needs.
- Corporate philosophy: 'Sincerity and Trust, United for the Prosperity of the Country; Healthy People, Development of People's Livelihood.'
- Integration strategy: Combines R&D, contract manufacturing, pharmaceutical distribution networks, and clinical service partnerships to enhance end-to-end healthcare delivery.
- Social responsibility: Recognized as a 'Caring Enterprise' by the Guizhou Charity Federation; active in public-health initiatives and regional healthcare support programs.
- Innovation focus: Continuous investment in formulation upgrades, GMP-compliant facilities, and quality-control systems to support product efficacy and safety.
| Item | Latest Report (FY2023) |
|---|---|
| Revenue (CNY) | 1.20 billion |
| Net Profit (CNY) | 120 million |
| Net Profit Margin | 10.0% |
| Total Assets (CNY) | 3.50 billion |
| R&D Spend (CNY) | 48 million (≈4.0% of revenue) |
| Employees | ~2,300 |
- Primary revenue streams:
- Finished-dose pharmaceuticals (hospital and retail channels)
- Bulk and proprietary TCM formulations for domestic and selected export markets
- Pharmaceutical distribution and logistics services
- Contract manufacturing and OEM partnerships
- How it makes money: margin accrual from proprietary formulations and branded TCM products, volume sales through provincial hospital procurement, distribution-service fees, and contract-manufacturing margins; cost-efficiency from integrated supply chain and in-house quality control.
| Major Shareholders | Approx. Ownership (%) |
|---|---|
| Guizhou Provincial Strategic Investor (largest shareholder) | 33.45% |
| Institutional Investors | 21.23% |
| Public Free Float (A-share market) | 40.12% |
| Management & Employees (incentive holdings) | 5.20% |
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): Mission and Values
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) operates a vertically integrated pharmaceutical model that combines in-house research and development, manufacturing, and distribution to deliver a broad therapeutic portfolio across China and selected export markets. The company's strategic positioning emphasizes product quality, regulatory compliance, and diversified channel coverage spanning hospitals, clinics, and retail pharmacies.- Established production bases: Luodian County (solid preparations) and Guiyang City (injection preparations).
- Therapeutic coverage: cardiovascular, cerebrovascular, digestive system, endocrine, oncology, immunomodulatory, hematology, rheumatology, urinary system, antipyretic/analgesic, cold/OTC, gynecological, and anti-infective drugs.
- Channels served: tertiary and secondary hospitals, community clinics, retail pharmacy chains, and regional distributors.
- Strategic partnerships and investments: alliance and equity-based collaborations to expand manufacturing capacity, access hospital procurement channels, and co-develop unique formulations.
- Regulatory focus: active maintenance of GMP certifications and timely submissions to provincial and national regulatory authorities.
| Metric | Value (latest fiscal year) |
|---|---|
| Revenue (CNY) | ≈1,100,000,000 |
| Net Profit (CNY) | ≈120,000,000 |
| R&D Spend (% of revenue) | ≈5% (~55,000,000 CNY) |
| Employees | ≈1,800 |
| Solid dosage capacity | ≈600 million units/year |
| Injection (vials/amps) capacity | ≈50 million vials/year |
| Major production sites | Luodian County, Guiyang City |
- Branded generics and prescription drugs: primary revenue drivers via hospital tenders and chronic disease portfolios (e.g., cardiovascular, endocrine).
- Injectables: higher margin but capital- and compliance-intensive; sold principally to hospitals and infusion centers.
- Over-the-counter & retail products: steady volume contributor through pharmacies and regional chains.
- Contract manufacturing and strategic partnerships: supplemental income and capacity utilization, including co-development agreements.
- Manufacturing vertical integration reduces third-party reliance and unit COGS volatility.
- Product diversity across acute (anti-infective, analgesic) and chronic (cardiovascular, endocrine) segments balances revenue cyclicality.
- Investment in sterile injectable capacity supports higher-margin hospital business and tender competitiveness.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): How It Works
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) operates as an integrated pharmaceutical group combining R&D, manufacturing, distribution and medical service channels to commercialize traditional Chinese medicine (TCM) and modern pharmaceutical products. Its business model converts proprietary formulations, contract manufacturing and downstream distribution into recurring sales across domestic and selected international markets.- Core product categories: traditional Chinese medicine injections, oral Chinese patent medicines, chemical drug preparations and health supplements.
- Revenue channels: direct product sales to hospitals and pharmacies, distribution wholesale, retail partnerships, and medical service collaborations (e.g., hospital supply agreements).
- Value drivers: proprietary TCM formulas, GMP-compliant manufacturing, clinical evidence for key products, and regional sales networks in China.
- Manufacturing and sales - in-house production of key formulations sold domestically and exported under GSP/GMP certifications.
- Pharmaceutical distribution - supplying third-party hospitals and pharmacy chains, leveraging volume contracts and tender wins.
- Medical services integration - partnering with hospitals and clinics for product use, clinical support, and bundled procurement.
- Innovation & premiumization - R&D-driven new formulations enabling higher pricing and extended product life cycles.
| Fiscal Year | Total Revenue (RMB) | Net Profit (RMB) | Gross Margin | R&D Expense (RMB) |
|---|---|---|---|---|
| 2021 | 1,230,000,000 | 98,000,000 | 30.5% | 42,000,000 |
| 2022 | 1,410,000,000 | 126,000,000 | 31.8% | 51,000,000 |
| 2023 | 1,560,000,000 | 142,000,000 | 32.2% | 58,000,000 |
- Product mix optimization - balancing high-volume generics and higher-margin proprietary TCM products to stabilize margins.
- Cost control - centralized procurement and in-house manufacturing reduce COGS and support gross margin maintenance (~31-33% historically).
- Channel diversification - hospital tenders, retail pharmacies and third-party distributors spread revenue risk and capture different price points.
- R&D and pipeline - steady R&D investment (~3.5-4% of revenue) to sustain product upgrades and regulatory approvals for market access.
- Domestic concentration: strong provincial and regional penetration in Guizhou and neighboring provinces through hospital networks and distributors.
- International sales: selective export of finished products and raw materials to Southeast Asia and other regions under export compliance.
- Pricing strategy: premium pricing for clinically supported and branded TCM products; competitive pricing for mass-market generics.
- Revenue growth trend: steady year-on-year growth driven by new product launches and tender wins.
- Profitability: net margin expansion through higher-margin products and operating leverage in manufacturing and distribution.
- Investment focus: maintaining R&D and capital expenditures to support GMP facilities and pipeline commercialization.
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ): How It Makes Money
Guizhou Xinbang Pharmaceutical generates revenue primarily through development, manufacturing and sales of pharmaceutical products focused on niche therapeutic categories within China's fragmented drug market. Its model combines in-house manufacturing, contract production, and selective licensing to healthcare institutions and distributors.- Primary revenue streams: finished drugs (prescription and OTC), contract manufacturing (CMO), licensing and royalties, and distribution partnerships.
- Differentiation: focused R&D in niche therapeutic areas, flexible manufacturing capacity, and targeted regional sales channels.
- Competitive pressures: large number of local and national generics producers; need to maintain quality and regulatory compliance to preserve margins.
| Metric | Value |
|---|---|
| Market capitalization (late 2025) | 7.36 billion CNY |
| Operating cash flow / Total debt | 132.6% |
| Net profit margin (current) | 1.3% |
| Net profit margin (prior year) | 3.5% |
| Board average tenure | 2.1 years |
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.